This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk08: Good morning. My name is Kevin, and welcome to Moderna's third quarter 2022 earnings call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. To ask a question during the session, please press star 1-1. Please be advised this call is being recorded. At this time, I'd like to turn the call over to Levina Talukdar, head of investor relations at Moderna. Please proceed.
spk11: thank you kevin good morning everyone and thank you for joining us on today's call to discuss moderna's third quarter 2022 financial results and business updates you can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investors section of our website on today's call are stefan boncel our chief executive officer stephen hogue our president arpa garay our chief commercial officer and Jamie Mock, our Chief Financial Officer. After prepared remarks, we will take your questions through 9.15 a.m. this morning. Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see slide two of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. With that, I will turn the call over to Stéphane.
spk18: Thank you, Lavina. Good morning, or good afternoon, everyone. Welcome to our Q3 2022 conference call. Today, I will start with a quick business review of the quarter before Stephen reviews our clinical programs. Papa will then take you through commercial dynamics, and Jamie will present financials. I will then come back to close before we take your questions. In the quarter, we reported $3.4 billion in revenues. We reported net income of $1 billion and cash investments totaling $17 billion. We now expect deliveries under advanced purchase agreements in the range of $18 to $19 billion in 2022, due to delayed deliveries from our 50-inch contract manufacturers, resulting in $2 billion to $3 billion of revenue deferrals into 2023. In Q3, we had to deal with a lot of complexity, launching two products, 1273.214 and 1273.222 at the same time, and also moving products from 10-dose vials to 5-dose vials. Q3 was actually our greatest delivery amount in terms of vial produced and was up over 20% the average for the previous three quarters. I'll probably share my thoughts on 2023 in a moment. In the first quarter, we repurchased over 7 million shares. The $3 billion share repurchase program we announced in February 2022 was completed. Since the start of our first share repurchase program in 2021, through the end of the first quarter, we have repurchased more than 23 million shares. Our third share repurchase program announced in August 2022 for an additional $3 billion in repurchase is ongoing. Let me now review the pipeline highlights and advances since our last update. I am very pleased with the important progress the Moderna team has made on advancing the pipeline closer to product launches, and at the same time, increasing the breadth of the pipeline. We've continued to progress our COVID booster programs and have received authorization around the world for both our COVID-1273.214 program, which targets Omicron BA.1, and 1273.222, which targets BA.45. We have, as you know, two respiratory vaccine phase three trials as we speak that continue to progress quickly. For flu vaccine, attended in September, we announced the first phase three immunogenicity study was fully enrolled. We expect now data in the first quarter of 2023. As a reminder, we plan to pursue an accelerated approval pathway for seasonal flu vaccine. We also started a phase three efficacy study with a flu vaccine and that trial is enrolling quickly. For phase three HIV vaccine, we are on track for data without this winter season. We were pleased to announce that Merck exercised their option to develop and commercialize a personalized cancer vaccine, mRNA-4157, paying Moderna $250 million in Q4. We and Merck will share costs and profit 50-50 for this program moving forward. We continue to expect data from our Phase 2 study for PCV in Q4 this year. In rare diseases, we are pleased to share at the R&D Day that we saw encouraging early sign of clinical benefit above PA and GSD1A, and announced a new development candidate for OTC. On slide six, you see our usual snapshot of Moderna in November 2022, showing the breadth of the pipeline. We have now 48 programs in development across vaccines and therapeutics. The company continues to grow, and we now have more than 3,700 Moderna team members. Last week, we were very pleased to announce as the top employer by science for the eighth consecutive year. We have now 15 commercial subsidiaries globally and a strong balance sheet of $17 billion to fund our continued growth. With this, I will now turn it over to Stephen to review the pipeline. Stephen? Thank you, Stéphane.
spk07: Good morning or good afternoon, everyone. This morning, I'll review our clinical progress. We've launched two vaccine boosters for the current fall-winter season to meet different market demands and have received authorizations or approvals worldwide for these vaccines. We previously shared that 1273.214, which targets Omicron BA.1, induced significantly higher titers than 1273 against the BA.1 and BA.4.5 sublineages in the clinical trial. mRNA 1273.214, is now authorized in the United Kingdom, Switzerland, Canada, Australia, the European Union, Japan, and other countries. For mRNA-1273.222, which targets the Omicron VA45 variants, the Phase 2-3 study is ongoing, and we expect data later this quarter. mRNA-1273.222 is authorized in the United States, and now also in the United Kingdom, Switzerland, Australia, Canada, the European Union, Japan, and other countries. Now moving to slide nine, I'll review our respiratory vaccines pipeline. I will cover the phase three studies in detail on the next slide. Here I want to highlight the progress in the earlier stage studies with our respiratory vaccines. mRNA 1020, 1030 for seasonal influenza is in a phase one, two study and is now fully enrolled. mRNA 1345 for RSV is in the pediatric population, is now fully enrolled in a phase one study. Moving now to our combination respiratory pipeline, where we have made meaningful progress, mRNA-1073, our combination vaccine for COVID and flu, is in phase 1-2 and is fully enrolled. I'm very pleased to announce that our combination COVID, flu, and RSV vaccine, or mRNA-1230, has also started enrolling in its phase 1-2 study. We announced a new development candidate, mRNA-1045, this one targeting combination of RSV and influenza, and that has started in its Phase I-II study. And lastly, in our combination vaccine pipeline, we also have a pediatric vaccine covering HMPV and PIV-3. That study is ongoing in the fully enrolled Phase I-B study. Finally, our endemic human coronavirus vaccine is in preclinical development, along with our pediatric RSV-HMPV combination vaccine. Now to review our Phase 3 flu and RSV programs on slide 10. For flu, our Phase 3 immunogenicity study in the southern hemisphere is fully enrolled with 6,000 participants, with a data readout expected in the first quarter of 2023. As we've previously noted, regulators have indicated support for an accelerated approval pathway for our seasonal flu vaccine candidate, pending the results from this study. We've also started enrolling our Phase III efficacy study in the Northern Hemisphere and have now enrolled more than 10,000 participants. Timing of this confirmatory Phase III efficacy readout will be driven by flu case accruals in the study and could come as early as this winter. Looking to RSV, our pivotal Phase III efficacy study in older adults has now enrolled more than 35,000 participants. As we've previously mentioned, our primary endpoints in this study are safety and vaccine efficacy. Timing of the phase three efficacy readout will be driven by RSV-CASIC rules in that study. As we're now in the midst of a very strong RSV season, we continue to expect that the results will be available this winter season. Moving on to our latent and public health vaccine portfolio, our CMV vaccine is ongoing in a phase three study. Our EBV vaccine to prevent infectious mononucleosis is in a Phase I study, while our EBV vaccine to prevent longer-term sequelae such as cancer and multiple sclerosis is in preclinical. We have two HIV Phase I trials ongoing, and our HSV and VZV vaccines are in ongoing preclinical studies. Finally, our public health vaccine for Zika is ongoing in a Phase II trial, and our Nipah vaccine is ongoing in a Phase I study. Now let's take a look at our therapeutics pipeline on slide 12. First, I want to note that AstraZeneca notified us that after a portfolio review, they are returning the rights to the IL-12 program to us. They are concluding the phase one study, and we will then evaluate next steps for the program for ourselves. Second, we're excited that our checkpoint vaccine has started dosing its first patients in a phase one study. And finally, our partner, Vertex, expects to submit an IND for our mRNA cystic fibrosis program by the end of this year. We recently shared updates on our personalized cancer vaccine, PA, and GSD1A programs at our latest R&D Day, and I will talk to those in more detail in the upcoming slides. Now, recall at R&D Day that we shared data from two rare disease programs. The first is in our propionic acidemia program, which is a multi-dose study, and as of September, we had accrued six patient years of experience on the drug and administered well over 100 doses. It has generally been well tolerated, which is encouraging. We've also seen an encouraging trend in the reduction of biomarkers and been observing a numerical decrease in the frequency of metabolic decompensation events, which is also really encouraging given the severity of these events for propionic acidemia patients. In the GSD1A program, We shared an early set of data from the first two patients in the first cohort. The study is a single ascending dose study that runs a fasting challenge in a controlled and safe environment in patients with GSD1A who are unable to normally fast or go without food for long periods of time without becoming hypoglycemic. Both patients in the first cohort have demonstrated that mRNA-3745 was well tolerated and showed an extension of fast duration and normalization of key biomarkers, including glucose, which we think is a very encouraging signal of activity. To close, I wanted to remind everyone that we expect our Phase II results from our personalized cancer therapeutic by the end of the year. The randomized study comparing PCV plus Keytruda versus Keytruda alone enrolled approximately 150 resected melanoma patients with a high risk of recurrence. The primary endpoint is recurrence-free survival. As Stefan mentioned earlier, our partner Merck exercised the option to jointly develop and commercialize mRNA-4157, and we look forward to sharing that data this quarter. With that, I will hand it over to Arpa.
spk12: Thank you, Stephen, and good day to everyone. I will start with a review of sales on slide 16. Sales to the U.S. were $1 billion in the third quarter and were mainly from deliveries of mRNA-1273.222 our bivalent booster targeting Omicron BA45. Sales to Europe of mRNA-1273.214 were also $1 billion, and the rest of the world totaled $1.1 billion. Through the first three quarters of the year, U.S. sales were $3.4 billion, sales to Europe were $4.5 billion, and sales to the rest of the world accounted for $5.7 billion. In both the three and nine-month periods, we saw geographical diversification of sales across these key regions. We recognize there are questions regarding the 2023 market and long-term COVID booster potential, and we wanted to walk you through how we are thinking about it. As we transition into an endemic market, there are important factors we considered in our commercial outlook. These include the ongoing medical need for COVID boosters and the potential size of the annual booster market. We used the seasonal flu market to frame the opportunity, and I will take you through our thinking on that in the next couple of slides. I will also detail some of the factors underlying the transition to the commercial market in the U.S. in 2023. I'll then wrap up the COVID section with an overview of our currently signed contracts, and our outlook for additional expected contracts in 2023. Finally, I'll close with a reminder of what's coming in 2023 from our respiratory vaccine franchise and potential launch timings that we shared recently at our R&D day in September. So starting with the medical need for COVID boosters, the chart on slide 18 compares hospitalizations and deaths associated with a seasonal flu and COVID over relevant time periods. For flu, we looked back at the past 10 influenza seasons in the US before COVID-related interventions disrupted the typical flu season. And for COVID, we looked at hospitalizations and deaths from October 2021 to September 2022, which covers the period of widespread immunity against SARS-CoV-2 and its variants, either through vaccination or infection. We believe this period is a close proxy to what population immunity to COVID could be in an endemic season. As you can see here on the chart, hospitalizations due to COVID during the past 12 months are three times higher than the 2017-2018 flu season, which represents a year with the highest medical burden within the 10-year period included in the analysis. and the deaths due to COVID are even higher, coming in at a rate of seven times higher than the same severe flu season. This comparison shows the higher medical burden of COVID in a period that we believe more closely approximates an endemic season and underscores the need for boosters in the endemic phase. It also helps frame the potential endemic annual COVID market, which I want to take you through on the next slide. To size the endemic COVID booster market, we start with the flu market volumes. Volume in the annual flu market is approximately 500 to 600 million doses around the world. The size of the market is highly dependent on the number of doses as well as global price as shown in the sensitivity table on the left-hand side of the slide. The prices shown here are purely illustrative to demonstrate a range of outcomes on global pricing. Ultimately, global price for COVID boosters will reflect sales mix and differential pricing across markets. Our endemic pricing will be focused on the value that the vaccine brings to healthcare systems around the world. As we move to an endemic market in 2023, key factors that will impact our volume of the year include the medical need, ongoing viral evolution, recommendations from public health authorities, and consumer motivation to vaccinate. So while we believe that volumes in the global endemic COVID market should approximate to at least 600 million doses over time, we believe it is too early to reliably predict the variables impacting the volume of doses in 2023. Turning to slide 20 and specifically addressing the transition to the commercial market in the U.S., We anticipate a more fragmented customer base, including private payers, health plans, pharmacy chains, individual pharmacies, and physician offices. We also anticipate reduced predictability in orders, seasonality of deliveries similar to flu vaccine deliveries, a shift to full distribution costs assumed by Moderna, as well as other major factors in the U.S., such as shifting to a single dose presentation, and continued innovation and product differentiation. Moving on to slide 21, we summarize the contracts that have been signed so far for 2023. We have advanced purchase agreements for the United Kingdom, Canada, Switzerland, Taiwan, and Kuwait, totaling $2.5 billion. Additionally, we expect deferrals of $2 to $3 billion from 2022. These deferrals are from the countries listed on the slide. Together, these advanced purchase agreements and deferrals total $4.5 to $5.5 billion in sales for 2023. Finally, and very importantly, we have a number of countries where we expect additional 2023 contracts to be signed. We are working to secure 23 orders in the US, EU, Japan, Australia, Asia, Latin America, and COVAX. and we expect to have visibility into these orders as contracting seasons begins later this quarter and continuing into next year. So to summarize the COVID outlook on slide 22, with the continued higher medical burden of COVID relative to flu, we expect the endemic COVID vaccine market could be as large or larger than flu market volumes over time. The US market is transitioning to a commercial market and we believe we are well-positioned to serve its evolving needs. And finally, we have established a base of confirmed contracts of $4.5 billion to $5.5 billion in 2023, to which we anticipate adding a number of important orders in the months ahead from key markets including the U.S., EU, Japan, and others. Now, before I close, I'm excited to review the formation of our respiratory vaccine franchise that we highlighted during our R&D day in September. As early as next year, we could be expanding into flu and RSV. And as we look at flu and RSV combined with COVID, they lead to more deaths annually than Alzheimer's, stroke, or diabetes in developed markets. As Stephen highlighted, depending on case accruals and vaccine efficacy, we could see data from our flu and RSV phase 3 trials this winter. We are actively preparing for the commercial launches for these additional respiratory vaccines and will leverage the COVID commercial infrastructure that we are currently building. With that, I'd like to turn it over to Jamie.
spk03: Thank you, Arthur, and hello, everyone. It's a pleasure to be here with you today. After two months at Moderna, I am even more excited about our company's future and the role we are playing in bringing a new generation of medicines to patients. For those of you whom I haven't had the pleasure of meeting yet, I look forward to working with you in the months and years ahead. Today, I will start by providing additional color on our third quarter results and capital allocation priorities and finish with the view on the key drivers on our remaining 2022 financial performance. Turning now to slide 25. Total product sales in the quarter of $3.1 billion decreased 35% year-over-year. The decrease was driven by lower sales volumes due to the timing of market authorizations for our updated COVID-19 booster vaccines and the related manufacturing ramp-up with our CMO partners. As a reminder, we received the marketing authorization for the U.S. on August 31st, for the European Union on September 2nd, and Japan on September 12th. We anticipate that product sales will be higher in the fourth quarter of 2022 than in the third quarter as we continue to deliver against our supply contracts for booster vaccines. Cost of sales was 35% of product sales compared to 15% of product sales last year. This includes a charge of $333 million for inventory write-downs related to excess and obsolete COVID-19 products, an expense for unutilized manufacturing capacity of $209 million, and a loss on firm purchase commitments and related cancellation charges of $102 million. These charges are driven by a shift in product demand to our Omicron-targeting COVID-19 bivalent boosters and costs associated with surplus production capacity. Research and development expenses were $820 million, an increase of 57% versus the prior year. The increase in R&D spend continues to be driven by our increasing and maturing pipeline including Phase III studies for RSV, flu, CMV, and COVID boosters. Selling general and administration expenses of $278 million increased by 65% year-over-year. The growth in spending was driven by continued investments in personnel and outside services in support of the accelerated commercial and overall company build-out. The effective tax rate of 14% compared to 6% last year As a reminder, we had a net operating loss carry forward of $2.3 billion at the end of 2020, which resulted in a non-recurring benefit to the reported tax rate in 2021. After-tax net income decreased by 69% to $1 billion. Diluted EPS in Q3 2022 decreased by 67% to $2.53. As a result of our share buyback activities, the diluted weighted average share count reduced by 22 million shares to 412 million shares as of the end of Q3 2022, compared to 434 million shares the prior year. Turning now to the year-to-date financial results on slide 26. Total product sales for the first nine months of 2022 were $13.6 billion, an increase of 26% year-over-year. The growth was mainly attributable to a favorable customer mix and higher manufacturing capacity to fulfill customer demand for the first half of 2022 compared to the first half of 2021. Cost of sales was 26% of product sales compared to 16% of product sales last year. The increase was driven by substantial demand reduction from COVAX, as mentioned in our Q2 earnings call, a shift in demand to our Omicron targeting COVID-19 bivalent boosters, and costs associated with surplus production capacity. Faster tax net income was $6.9 billion, a decrease of 6% versus prior year. The decrease in net income was primarily due to higher cost of sales, higher other operating expenses, and a higher tax rate. Diluted EPS decreased by 3% to $16.46. Turning to cash and cash deposits on slide 27, we ended Q3 2022 with cash and investments of $17 billion, compared to $18.1 billion at the end of the second quarter. The decrease reflects the share buyback in Q3 of $1 billion and a federal tax payment of $0.8 billion. The ending balance of cash deposits for future product supply at the end of the quarter was $3.8 billion. Now turning to slide 28, our capital allocation priorities remain unchanged. Our top investment priority has been and will continue to be reinvesting in the base business across multiple areas. R&D spending was $2.1 billion in the year-to-date September period, a 55% year-over-year increase. We continue to be excited about our MRNA platform and now have 48 development programs with multiple ongoing studies now in phase three. We increased our year-to-date capital expenditures by 88% year-over-year to $308 million. as we expand our manufacturing footprint. We also continue to invest in our commercial and digital capabilities, as well as the overall company build-out. Our second investment priority is to seek attractive external investment and collaboration opportunities to further expand the reach of Moderna's technologies and capabilities. We are considering attractive opportunities that enable and complement our platform and take a disciplined approach in evaluating potential outside investments. We are in multiple active discussions regarding additional external collaboration opportunities. Then after evaluating internal and external investment opportunities, we then assess additional uses of cash. In the third quarter of 2022, we repurchased 7 million shares for $1 billion. Year-to-date through September 30th, we repurchased 20 million shares for $2.9 billion. In October, we completed the $3 billion authorization approved in February 2022 and began to utilize the additional $3 billion August authorization. Now let's turn to our 2022 updated financial framework on slide 29. We now expect delivery in 2022 against signed advanced purchase agreements of $18 to $19 billion, reflecting deferrals of $2 to $3 billion into 2023 due to short-term supply chain constraints. This total includes expected negative foreign exchange impacts compared to the contract value at signing, which we estimate to be approximately 1.5% of sales for the full year 2022, assuming current exchange rates remain through the year end. Our total cost of sales includes the cost of goods manufactured, third-party royalties, as well as logistics and warehousing costs. We now expect our full year 2022 reported cost of sales to be in the 26 to 28 percentage range, driven by the previously mentioned costs incurred year to date a range on our Q4 volume, and potentially further charges due to product updates. For R&D and SG&A, we continue to expect full-year expenses to be approximately $4 billion, driven by our maturing development portfolio and the global scale-up of our company. Based on current tax laws, we continue to expect our 2022 effective tax rate to be in the low to mid teens, as a result of benefits from the foreign-derived intangible income driven by our international business mix, and stock-based compensation deduction. Finally, regarding capital expenditures, we now expect capital expenditures to be approximately $0.5 billion, slightly below the previous range of $0.6 to $0.8 billion, driven by the timing of project completion. This concludes my remarks concerning the financial performance And I will turn the call back over to Stephan.
spk18: Thank you, Jamie, Arthur, and Stephen for this update. Before opening to Q&A, I just want to review some of the key priorities as we close out this year and look into 2023. For the remainder of the year, we'll continue to focus on delivering our updated Omicron boosters and drive 2022 sales. We are already working on 2023 sales contract in Europe, Japan, and as you heard from Arfa, around the world. Arfa and their team are also setting up the US team and scaling it so that we can go private in the US market in 2023. We continue to execute on our pipeline. We look forward to be able to present when we have it, the phase two data of PCB expected before the end of the year, The team is doing a great job to continue to enroll our phase three study for flu and RSV and CMV, and I'm excited to see the advancement of our rare disease programs. Looking to next year, ARPA and the team and the entire organization, including manufacturing, is preparing for multiple vaccine launches in the year, including commercial COVID market, as well as potential for therapeutic programs to move very quickly in phase three. And finally, we hope that many of you can join us next week for our first ESG Day on November 10th. The virtual event will be available from our webcast. With this, we'd be happy to take your questions. Operator?
spk08: Ladies and gentlemen, if you have a question or a comment at this time, please press star 1-1 on your touchtone telephone. We'll pause for a moment while we compile our Q&A roster.
spk09: Our first question comes from Salvin Richter with Goldman Sachs.
spk08: Your line is open.
spk16: Good morning. Thanks for taking my questions. On pricing here for the COVID vaccine, Pfizer's guiding to a price of 110 to 130 in the private market. Is this in line with what your discussions thus far suggest? And when do you think the private market will emerge next year? And then a second question here, you were talking about some of the cost burden for next year with distribution costs and building out the commercial infrastructure around flu RSC and trials. Could you just give us some directional color on the OPEX situation as we look to the forward?
spk12: So I can take the pricing question. So first, you know, I'm not in a position to comment on competitor pricing, but as we think about our pricing as we evolve from a pandemic setting to an endemic setting, The real focus for us is on ensuring that our vaccines are priced based on the value that they provide to the healthcare system and reflect the cost effectiveness guidelines that are set by public health authorities around the world. So for here in the U.S., that would be ACIP. I think it's important to note that some of the pricing guidance that has been released in the past is really at a gross level, and we do anticipate some discounting across different channels. Additionally, here in the United States, as we evolve into the commercial setting, it's also important to remember that for all ACIP-recommended vaccines, there is a zero out-of-pocket cost for consumers. So, from a consumer access perspective, we do expect that the pricing will not be a barrier to uptake.
spk03: And, Salvi, maybe I'll take the cost part of that. So, yes, our costs will change in an endemic mode. Number one, there are presentation preferences, moving more to prefilled syringe and single-dose files that I think will be different year over year. We have to continue to invest in bivalent vaccines, as well as Moderna will now pick up the distribution costs moving forward, particularly in the United States. And so, yeah, our cost profile will change, and we'll come out and update in terms of what that means at a later date.
spk09: Thank you. One moment for our next question. Our next question comes from Matthew Harrison with Morgan Stanley.
spk08: Your line is open.
spk17: Great. Good morning. Thanks for taking the question. I was hoping to ask on PCV, just given that this is a Phase II study that's proof of concept, a p-value greater than 0.05 could be considered a success in the study. So maybe you could just help us think about how you're thinking about success in the study. And then just given that it's an open-label study, how much data is available to you internally? Thanks.
spk07: Great thanks for the question. So, so, as you said, it's a phase 2 study, but it's actually quite sizable. 1 is 150 patients and they were randomized 2 to 1. so 100 patients have received the combination therapy and 50, the standard of care, which, in this case is key Truda. That's actually quite a sizable sample and does allow for us to look at efficacy. Now, it is a Phase II study, and so we didn't pre-specify a statistical threshold that we'd want to hit, but we are looking at hazard ratios across that, and we will get p-values. I won't comment on a specific p-value or hazard ratio at this time. It's premature to do so. But obviously, we are looking against standard of care to demonstrate a significant benefit over that standard of care. It's just important to note that the study wasn't powered for that at 150 participants. We will be looking to that hazard ratio and the p-value as indicative, and then depending upon the strength of that result, if it is in fact, as you said, a p-value less than 0.05 and there's a very strong result, we will then make our subsequent decisions about how to proceed forward with development. Obviously, the stronger the benefit in terms of hazard ratio and the lower the p-value, the more we'll want to move very quickly towards advancing that program.
spk09: Thank you. One moment for our next question. Our next question comes from Edward Tennoff with Piper Sandler. Your line is open.
spk02: Great. Thank you very much and congrats on all the progress. I appreciate all the detail on sort of the outlook both for the COVID market and as we move forward. Questions back to my favorite topic, the orphan diseases. Proven concept in him from the 1st programs. Is there a desire to be expanding the pipeline similar to what you did with vaccines upon proven concept with Kobe? Thank you very much.
spk07: Thanks, Ted, for the question. And so I think the short version is yes, absolutely. You know, in any of our modalities, whether they're cancer vaccines or our infectious disease vaccines or now our orphan disease, where we believe we've achieved a technological proof of concept, where we've achieved what we wanted to in patients, we look to rapidly expand the number of diseases and implications that we can bring forward that technology in. And in the case of, you know, orphan rare diseases, as we shared, we are extremely encouraged by the data across two different diseases using two different medicines that now suggest we have, obviously, acceptable safety and tolerability profile, which is of primary importance. But more importantly, for efficacy, we're starting to see really encouraging results in terms of biomarkers or even pharmacodynamic readout, that potential of benefit for patients. And so given the strength of those two prior results, we've actually moved quickly to expand our pipelines. We have a number of other programs that are already publicly disclosed and moving forward in clinical trials. Some, including MMA, are already in clinical studies. And as I mentioned at our R&D day, we're looking to substantially expand that pipeline of programs. And so we announced the OTC program as one instance of that just a month ago, but you can expect that we'll be adding substantially to that. Our goal will be to more than double that pipeline in the years ahead as we expand our investments in rare diseases on the back of that de-risked clinical data.
spk08: Great. Excellent. Thank you, Stephen.
spk09: One moment for our next question. Our next question comes from Michael Yee with Jefferies.
spk08: Your line is open.
spk05: Hi. Good morning. Thanks for the questions. Maybe a question for Stephen. we've had two players read out results. I think one is 80% plus or minus, one 66% plus or minus, depending on the endpoints. So I wanted to ask you how you view the bar in terms of being competitive and where there is some differentiation opportunity for your RSV vaccine that could read out soon. So talk a little bit about that. And then just as a follow-up to PCV, again, just to clarify, Merck had opted in Can you comment on, I guess, the idea of the timing just before the data, whether they had sufficient information, or maybe just talk a little bit about the implications of that opt-in just before the data? Thank you.
spk07: Thank you for the question, Michael. So, first of all, RSV, obviously, we're incredibly encouraged by the results that have been seen by other vaccines. Given our platform has previously demonstrated its potential in COVID specifically in respiratory vaccines, We think it bodes well for us in terms of that study. You know, there's a bar that's been established in terms of severe disease, as you referenced, in the 80% range. We are looking at three symptom or, you know, quote, unquote, severe disease. It's hard to compare between the studies. They're not conducted at the exact same time, and they don't always have exactly the same definition, as you know. But we would absolutely hope and expect that the type of efficacy we're going to see against severe disease will be on par with, and I would even hope for better, than what's been seen by others. It's certainly been the case with our platform technology compared to others in terms of COVID that we've been able to see those sorts of potential benefits. I'll also note that we looked at titers, and we previously shared our titers as well as other companies have from their early clinical phase one and phase two results, and we believe that the boosting of neutralizing RSV titers against both RSV-A and RSV-B that we were achieving was on par, you know, you could You could always argue perhaps better or worse, but on par with what others had seen. So we're quite encouraged by that, and I think we're looking forward to the RSV efficacy results over this coming winter. Our bar for this is to be as good or better than others have been. In terms of PCV, In terms of PCV, Merck has opted in, as you said, and I know Matthew asked the question as well. It is an open-label study, as we previously disclosed, and so we have been following events through that study, those that have received the cancer vaccine in combination with PCV versus those that have not. And as we've now passed the one-year mark for follow-up of the last patient to be randomized in that study, we now have at least a year of follow-up and then many cases, two-plus years of follow-up across those two different cohorts, those that received Convo and those that received standard care Keytruda. That data was known to us and Merck, but it's important to note that that's an ongoing, uncleaned, and not primary analysis. And so while it is open label, the correct thing to do at this point now is begin the closing process, get all of the scans, review all of the data associated with the clinical outcomes, make sure nothing was missed, And in that cleaning process, then finalize that database and conduct the primary analysis of the study, which is to evaluate the hazard ratio and the statistical significance of that hazard ratio between the two arms. That's actually the process we're undergoing right now. And it's important that before we make a decision on whether that data is positive or negative and the strength of that positivity, how quickly we move forward, per Matthew's question, into whatever the next stages of development are, that we conduct all of the right diligence on those data sets. And that's the work that's ongoing right now. While Merck made their opt-in decision, which was really more calendar and contract-driven, based on obviously having access to that open label information, the really important analysis, the primary analysis, the one on which we will base our decisions of what to do next, as will regulators and others, is the one that we're trying to conduct right now and is not yet completed. But we do expect that result in this quarter. Thanks. Very helpful. Appreciate it.
spk08: One moment for our next question. Our next question comes from Gina Wang with Barclays. Your line is open.
spk01: Thank you. Steve, maybe just follow with your comments on Merck. Just want to confirm that Merck does see in the open label data for the recovery and free survival rate. And then also wanted to confirm that, you know, the control arm, the P1 model, that will be in line with historical data that's in the low 70s. That would be the rate. And also, how would you share the data for the PCV phase two data? Another question is regarding slide 19, the global COVID market opportunity. Since we expect significant increase in price in the U.S., what is your expectation for the ex-U.S. price change across major markets since you're giving like $20 to $40 price range?
spk07: So, Gina, thanks for that question. So, again, it was not a continuous data set. It was an open-label study. And so, for our agreement with Merck, they had the right to know what do we know about the program at the point at which they had to make their decision about whether to opt in or not. And so, of course, what we did is we provided them the access to the data of the study at that point in time. And as you all have noted, They elected to opt into that program, and we are encouraged by that decision on their part. They obviously do have a tremendous amount of experience, and so in terms of the control arm, you obviously have the Keynote 54 study, which is their prior registrational studies. They have experience of what to expect in a control arm, and I think you can infer whatever you'd like from their decision to just say that they believe it's worth opting into that program and proceeding to the primary analysis that we're conducting right now. We will obviously be able to compare the control arm, the 50 patients who just received Keytruda as standard of care, against the registrational studies that others have done and actually the many years of patient experience that companies like Merck and others have, just to be confident that, in fact, if we are seeing a difference between We are seeing a hazard ratio difference. It's not a difference in terms of that control arm, which will bode well because, again, patients were randomized in this study. Now, in terms of the data we'll have and share, at this point, all we'd expect to share this quarter, once we've completed the analysis, the primary analysis on efficacy in the study, is just the top-line data in terms of PCV, which, as I mentioned previously, is looking at the hazard ratio and then a characterization statistically of that. In subsequent and appropriate fora, including meetings and otherwise, we will look to then share the folder data set over time.
spk12: And then I can take the pricing question. Your question was primarily around ex-U.S. pricing and our expectations. A couple of factors are coming into play here. The first is the timing of where and how quickly ex-U.S. markets are going to be shifting from more of a central procurement pandemic situation setting to an endemic setting. So we're looking at how different regions and countries are going to be shifting back towards a more endemic or a commercial approach. When we get to that position, we will be, again, pricing the vaccine according to the value that it provides in different healthcare systems around the world. And again, following established systems around cost effectiveness guidelines based on the country regulations and the public health authority guidance. The overall global average price we do anticipate will be largely driven by the regional mix, so it is hard to predict what that price will end up being, but we'll continue to share more as we see evolving demand as well as evolving pricing. Thank you.
spk09: One moment for our next question. Our next question comes from Tara Bancroft with Cowan. Your line is open.
spk15: Hi, guys. Thanks for taking the questions. So is it fair to say that the 2023 signed APAs of the $4.5 to $5.5 billion is the floor? And what minimum revenue do you think could be added from the geographies that you're expecting contracts from? And related to this, then, to what extent does it include sales in the key markets that were mentioned in the press release? Like, for example, does it include the option from the latest U.S. agreement? Thanks.
spk12: Thank you for the question. So the $4.5 to $5.5 billion is the floor sales that we anticipate in 2023, as we already have signed APAs as well as deferrals from 2022 into 23. This number does not include options from the U.S. government. And we do anticipate additional sales coming from key markets such as the US, EU, Japan, Australia, as well as regional sales in Latin America, Asia Pacific, Middle East, and COVAX. So again, to answer your question specifically, this is what we anticipate to be the floor, but still unknown in terms of the total opportunity as we evolve, particularly in the US market, into a commercial setting.
spk09: Thank you. One moment for our next question. Our next question comes from Jessica Fire with JPMorgan.
spk08: Your line is open.
spk14: Hey, guys. Good morning. Thanks for taking my question. Are the short-term supply constraints mentioned as the reason for delivery delays resolved at this point? How does bivalent booster uptake so far this fall compare to your expectations? And as it relates to China's potential orders of Western mRNA vaccines, what's your level of optimism that that could come to fruition within some reasonable timeline, say the next year or so? Thank you.
spk18: Sure. So, Stephane, I'm going to take the first question on supply, and then I'll turn to Arthur for the commercial pieces. As I shared in my remarks, we actually had to deal with a very complex third quarter from a manufacturing standpoint. You know, not launching one product, but two. Doing this kind of in the record times, as you are aware, the FDA informed us at the end of June that they wanted to be a five product for the U.S. And that product was available in pharmacies, you know, label the weekend. And the shift from 10 doses per vial, which is what we sold with 1273, and for the first time selling five doses per vial, basically doubling the number of vials needed. the same number of doses. And so we've had quite a number of pain points with pre-finish manufacturers. We are working for a lot of those issues. A lot are solved, a lot are still being solved as we speak. There are many lessons to be learned that we are working on to put robust fixes for the end of the year, but also so that we are in a much better place for the fall of 2023.
spk12: Sure. So, the first question around vaccine uptake. We are seeing some variability around the world in terms of vaccination rates with the best data thus far really coming from the US market. As we look at 2022 vaccination uptake versus 2021, specifically for COVID boosters, We're actually tracking a similar pattern, and it's a little bit early to see what November, December, and the rest of the fall and winter season will look like. But the early rates, while in absolute terms are fairly low, they are tracking the trends that we expected compared to last year. Around the world, we are seeing some markets with very high uptake of vaccination rates, really driven by public health authorities. And in other markets, we're still looking at sort of the dynamics that have played out this year with populations have recently gotten their fourth booster in the summertime, and regulatory bodies recommending that they wait a few months before they get their fifth booster. So I think more to come as we continue to track around the world, but the early signs of uptake are encouraging. Your last question on China. We continue to look at the opportunities in China. Nothing new to report here as of now, but it is certainly a key market of interest for us commercially.
spk15: Thank you.
spk08: One moment for our next question.
spk09: Our next question comes from Jeff Meacham with Bank of America.
spk08: Your line is open.
spk04: Morning, guys. Yeah, thanks for the question. Just had a couple. Just wanted to follow up on your last comment. You mentioned booster adoption has been mixed depending on geographies. Is this something that Moderna expects to further invest in with regard to value of boosters, additional follow-up, and studies? That's the first question. The second one, maybe more for Stefan, the balance sheet remains pretty strong. you guys have done some buybacks, but we haven't seen sort of a cluster of acquisitions or any sort of real capital allocation. Where would M&A sort of fall in your priority list with uses of cash, and does that change as COVID continues to sort of wind down with regard to the revenue base, 23 over 22, and maybe even more modest going forward. Thank you.
spk12: So to the first question on if we are investing in the vaccination rates, as I shared earlier today, the medical need continues to be clear for COVID booster vaccination, especially as we compare it to the hospitalizations and deaths compared to flu. What we're really doing is partnering with governments and public health agencies to share the data that we have in terms of the ongoing medical need at a country level, as well as the value of COVID booster vaccination in their populations. And it's this partnership with the public health authorities that's really driving increased urgency and action around vaccination. So that's our approach. So we believe public health authorities are in the best position to encourage a vaccination for their populations.
spk18: Thanks, Harper. And on the balance sheet side, I mean, our business strategy, as Jamie noted in his remarks, is unchanged. As you know, we are looking and have already signed deals in terms of technology licenses and also looking at M&A. As we've said before, you know, we stay focused on nucleic acids. We don't really think it's a good strategic use of our capital to buy small molecule assets or large molecule or cell therapy or others. We really want to stay in nucleic acid. The Big E team is very active, as Jamie knows and his team knows. They are doing a lot of work. We're reviewing a lot of things. As I've said in the past, we remain disciplined in terms of understanding risk, either on the technology side or on the biology side. I'm not saying value, we're here to create value, not to manage press release. But the team is very active. We are looking at diligence on a regular basis, but not everything that we look at comes out to be something we think we can create a lot of value with. But we continue to look, and I would not be surprised if we continue to add partnerships in the most headquarters to come.
spk08: Great.
spk18: Thank you, guys.
spk08: One moment for our next question. Thank you. Our next question comes from with UBS. Your line is open.
spk00: Thanks so much for taking the question. Just another one on RSV. In terms of thinking about mRNA as a vaccine modality in the context of RSV as we move beyond COVID vaccines, I guess how are you thinking about the potential for mRNA and potential advantages relative to other more traditional vaccine modalities in the context of RSV? And I guess what we could learn from some of the upcoming readouts, both, I guess, for the opportunity in RSV, but also what it could tell us about mRNA potential and vaccines relative to other modalities more broadly. Thanks.
spk07: Great. Well, thanks for the question. So, you know, first, we have previously demonstrated with our platform in COVID and, in fact, in some recent publications even in flu, that we generally see a really broad-based and balanced immune response. So we tend to see very high T cells and cell-mediated immunity, and I would argue some of the highest, if not always the highest, antibody-neutralizing titers. And both of those are really important as you start talking about older adults and respiratory infections, which is probably why we tended to see higher efficacy with the mRNA platform than other approaches in that high-risk population, including in COVID, you know, over the last couple of years. And so those features of the platform, the ability to generate really strong cell immunity, boost T cells, which are important for preventing severe disease, but also pair that with achieving very high titers for a seasonal protection, where, again, you get high neutralizing titers, which provide a barrier to the amount of infection that you're going to get, which is really, really important for older adults because their cell-mediated responses, their innate immune system just isn't as strong even with a great vaccine. And it's that combination that we think defines our advantage from a platform perspective and why we're so excited about developing a portfolio of respiratory vaccines across all the leading killers in that space, viral killers in that space for older adults. And ORSV just fits right into that. As we all know right now, there is a huge unmet need in that space. We're very pleased to have enrolled, fully enrolled that phase three study. And we're going to, you know, we were actually quite pleased with the titers and cell media immunity that we saw in early development, some of which we presented publicly. So, we're looking forward to that efficacy readout. In terms of other approaches, you know, let's also just celebrate that, you know, recombinant protein and viral vector and adjuvanted approaches have all shown really exciting progress in the last really year, year and a half, across a range of companies. RSV is a huge unmet need. It will take many different approaches to have an impact there. And if anything, I think the success of others gives us optimism that our approach is going to also be successful, but there are likely going to be many different solutions to this for older populations. We do believe that our platform has an advantage, but given the success of the other vaccines and really, I think, quite encouraging efficacy results, it's important to note that there are many good, successful options out there, and it may not always be possible to differentiate between them, but we hope to be in that first class.
spk09: Great. Thanks. One moment for our next question. Our next question comes from Joseph Stringer with Needham. Your line is open.
spk06: Hi, good morning. Thanks for taking our questions. Just a clarification on the deferrals from the 2022 contracts, the two to three billion. Are those locked in signed APAs and they're just being deferred to 23 or is there any optionality built into that? And then the second question is just broader based pipeline You know, you're expanding pipeline, 48 programs, 35 clinical trials. But I was curious if you could comment on the relative mix of the pipeline, respiratory vaccines, immuno-oncology, rare disease, you know, where it stands now and how you sort of see that evolving and that relative mix of the pipeline programs over time.
spk03: So, maybe I'll take the first one quickly. So, yes, those are locked in advanced purchase agreements for 2023, and so they're just shifting to the right from 2022. Great.
spk07: And on the broader question of the pipeline, as you mentioned, we've got, you know, 48 programs now, multiple Phase 3s ongoing, with some we hope to be quite imminent readouts. You know, as you look at it, right now, we have most of our late-stage pipeline is respiratory vaccines, for sure, right? We have four programs there. And we expect the flu and RSP data to come up quickly and we will then move rapidly in respiratory into combination vaccines. And so we have 3 adult combination vaccines and clinical studies. We have 2 pediatric respiratory combination vaccines that are that are moving forward and that you should expect to expand into very quickly. We would hope registrational studies over the coming. period, which will allow us to then build out what we hope will be the best respiratory portfolio, both from a monovalent vaccine perspective, but most importantly, from combinations against the viruses that matter in the different populations that we really want to protect, particularly older adults and the very young. So respiratory will be a growth area for us for the near term. But you'll start to see some diversification, again, talking about the late stage. We already have a CMV phase three program, which is up and running and enrolling, has been, and you should expect us in our latent virus vaccines to add additional late-stage programs. We're quite passionate about Epstein-Barr virus, as you all know, and we expect to move that in. And so you'll start to see some first diversification in terms of our latent virus portfolio, some that's already happened with CMV. The couple of things that will come quickly as well are we hope that the readout from our personalized cancer vaccine therapeutic vaccine program, and it's really a therapeutic because we are preventing cancer from occurring, but we're intervening in somebody who's got that cancer already. And because of that, it really has a therapeutic profile to it as an intervention. And that therapeutic readout that we expect to have over the next month or so, this quarter, will trigger, if it's successful, moving into pivotal stage studies. And as we all know, immuno-oncology is obviously a competitive space. It's a space where there's still substantial need to improve upon the current IO therapy. And there are many different histologies and types of cancer in which it will make sense to develop a program if we show a benefit. So that expansion could happen very quickly and will be the large diversification into oncology and the therapeutic context outside of the vaccine space. And then the last one is late, is rare diseases, which we spoke about. We have a couple of programs that have already started to show some very encouraging results, both pharmacology and potential clinical readouts. And as soon as we decide on doses for, for instance, the propionic acidemia program and get confident that we've got alignment with regulators in the path forward for that program, you should expect us to move into pivotal studies there as well. And then, as I said in answering a prior question, That will not just be a one-off for us. Once we really believe we've got a modality, we will be bringing forward many programs in succession in parallel there. And so as you look forward on how do we think about the diversification of the pipeline to the bigger question, it really is a question of time horizon. You know, right now, it's a lot of respiratory and latent. Very quickly, though, we expect to be both expanding that respiratory and expanding our move into therapeutics, particularly cancer and rare metabolic disease. And that could happen in quite short order. based on upcoming clinical readouts.
spk06: Great.
spk09: Thank you for taking our questions. One moment for our next question. Our next question comes from Manny Furuhar with FDB Securities.
spk08: Your line is open.
spk13: Hi, and good morning. This is Lilian Nusango. I'm for Manny Furuhar. I just have a question related to volume to be expected. So I know that your volume production, you'd mentioned that, you know, you'd exclude 2023 based on because of the variability there. But I was wondering for 2023, how much of COVID volumes or COVID burden used to anticipate to be driven by the APAs? And also, as you move toward more of an endemic model for the COVID vaccine, do you continue to anticipate APAs in the future? Thank you.
spk12: Sure. Thank you for that question. As I outlined in terms of the volume expectations for next year, outside of the signed APAs, we are looking at a number of variables that could impact the total volume. So in the long term, we do believe we should approach this 500 to 600 million volume comparable to the flu volumes that exist today. In 2023, there will be a range depending on the viral evolution, the ongoing medical need across different regions, where we see public health authorities coming out with recommendations, as well as just a broader consumer appetite to vaccinate. So the reason for that sensitivity on the volume that I shared earlier is we still have a number of variables as we're continuing to transition into an endemic stage. And so in the short term, We don't have a clear picture of that total volume and what that could look like, but we do believe, from a medical perspective, over time we should be approaching at least the same volumes as the flu market.
spk09: Thank you.
spk08: And I'm not showing any further questions at this time. I'd like to turn the call back over to Stefano Betzoff for any closing remarks.
spk18: Well, thank you, everybody, for joining the call today and for your thoughtful questions. We look forward to speaking to many of you in the days to come and also welcoming you next week for our first ESG day. Have a great day.
spk08: Bye. Ladies and gentlemen, this does conclude today's presentation. You may now disconnect and have a wonderful day.
Disclaimer